Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.
This study has been completed.
Information provided by (Responsible Party):
First received: January 10, 2007
Last updated: October 4, 2012
Last verified: September 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Primary Completion Date:||August 2007 (Final data collection date for primary outcome measure)|